Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials

PURPOSE: Two phase I, open-label trials in healthy subjects assessed whether co-administration with CYP3A4/CYP2C19 inhibitors, itraconazole/fluconazole (study A), or CYP3A4 inducer, rifampicin (study B), affects the exposure, safety/tolerability and pharmacokinetics of selumetinib and its metabolite...

Descripción completa

Detalles Bibliográficos
Autores principales: Dymond, Angela W., So, Karen, Martin, Paul, Huang, Yifan, Severin, Paul, Mathews, David, Lisbon, Eleanor, Mariani, Gabriella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Pharmacokinetics and Disposition
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226997/
https://www.ncbi.nlm.nih.gov/pubmed/27889832
http://dx.doi.org/10.1007/s00228-016-2153-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226997/
https://www.ncbi.nlm.nih.gov/pubmed/27889832
http://dx.doi.org/10.1007/s00228-016-2153-7

Ejemplares similares